

COST ACTION CA 17140 **NANO2CLINIC** CANCER NANOMEDICINE - FROM THE BENCH TO THE BEDSIDE **Department of Anaesthesiology and Intensive Care Medicine** Research Group Molecular Mechanism of Life-Threatening Infection


# Theranostic nanotherapy of acute life-threatening conditions

Jun.-Prof. Dr. Adrian T. Press adrian.press@med.uni-jena.de

17.06.2022 | Magdeburg, COST 17140




#### Sepsis – a life-threatening organ dysfunction




responses when they encounter each other



#### **Sepsis – a life-threatening organ dysfunction**



Both, the pathogen and the host carry out various stress responses when they encounter each other




Each pathogen has adaptive and unique strategies to evade the immune response.

The immune system and other tissues orchestrate and carry out a response tailored to fight the infection.



#### The liver in sepsis




- **40% of patients** with sepsis suffer liver failure
- 50% mortality risk in sepsis
   with liver failure
- 27 to 48% of long-term mortality is associated with cholestasis.




4 Horvatits Hepatology 2019, Beyer et al. BMC Mol Med. 2022, in revision

#### **Polymethine dyes with tissue specific clearance**







#### **Polymethine dyes with tissue specific clearance**








#### **Liver function: Live**




sinusoid
hepatocyte
canaliculus




Mice injected with an **DY-635** (an ICG analogue) which is cleared by **hepatocytes** exclusively. The liver is viewed by intravital microscopy.



## DY-635 is a substrate for organic anion transporter in the liver






DY-635 is a strong competitive inhibitor of human OATPs




### **PI3K**γ in sepsis



9 Recknagel et al. PLoS Med. 2012, Press et al. EMBO Mol Med. 2021


**UNIVERSITATSKLINIKUM** Jena

\*




AS605240 is a potent PI3K $\gamma$  inhibitor with strong immunosuppressive properties






AS605240 is a potent PI3K $\gamma$  inhibitor with strong immunosuppressive properties





#### AS605240 is a potent PI3K $\gamma$ inhibitor with strong immunosuppressive properties






ns ns \*\* Ż AS605240 (pmol mg<sup>-1</sup> tissue)

AS605240

LC-MS detection of AS605240 1 h after 0.1 mg/kg T-LipoAS, 1 mg/kg AS i.v.

**UNIVERSITÄTSKLINIKUM** Jena








min

ഹ

-








LC-MS detection of AS605240 1 h after 0.1 mg/kg T-LipoAS, 1 mg/kg AS i.v.


Shkodra Pharmaceutics 2020 Press et al. EMBO Mol Med. 2021 Foo et al. Biomed. Optics Express 2022







**Vuniversitätsklinikum**jena

### Targeting AS605240 prevents immunosupressive effects in septic mice










pathogen load

**Universitatsklinikum**jena

### Targeting AS605240 prevents immunosupressive effects in septic mice








load

pathogen




### Targeting AS605240 restores liver function in septic mice







## Targeted delivery of PI3Kγ inhibitor AS605240 improves survival in a murine sepsis model



#### Only targeted PI3Kγ delivery improved survival significantly





#### Targeted delivery of PI3Kγ inhibitor AS605240 improves survival in a murine sepsis model



20

### OATP-dependent uptake of DY-635 in CML stem cells






**UNIVERSITATSKLINIKUM** Jena


21 Ernst et al. Mol Ther Oncolytics. 2020

### OATP-dependent uptake of DY-635 in CML stem cells





#### **DY-635 as theranostic agent for CML therapy?**




Scale 2 µm

UNIVERSITÄTSKLINIKUM Jena


23

#### **DY-635 as theranostic agent for CML therapy?**






#### **DY-635** as theranostic agent for CML therapy?



IVERSITÄTSKLINIKUM Jena

#### Where are we heading? – Surface architecture in nanocarriers



**UNIVERSITÄTSKLINIKUM**Jena

26 Muljajew et al. ACS Nano 2021